NEULAND LABORATORIES LIMITED

Flat No.204, II Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad-500 016. A.P., INDIA.
Phone : +91-40-30211600, 23412934, 66518682, Fax : +91-40-23412957
E-mail : neuland@neulandlabs.com URL : www.neulandlabs.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2011

Amount in ₹ Lacs, except share data

Sl. No.	Particulars	Quarter Ended 30.06.2011 (Unaudited)	Quarter Ended 30.06.2010 (Unaudited)	Year Ended 31.03.2011 (Audited)
1	(a) Net Sales / Income from Operations	10,231.21	8,903.72	39,357.23
	(b) Other Operating Income	164.82	56.72	424.21
	Total Income	**10,396.03**	**8,960.44**	**39,781.44**
2	Expenditure			
	(a) (Increase) / Decrease in stock in trade and work in progress	(626.20)	(199.71)	(317.19)
	(b) Consumption of Raw Materials	7,471.94	6,151.47	25,308.09
	(c) Employees Cost	659.61	621.71	2,606.03
	(d) Depreciation	365.15	379.33	1,541.12
	(e) Manufacturing Expenses	842.69	782.19	3,335.09
	(f) Administration, Selling and Other Expenses	857.05	991.37	3,998.75
	Total Expenditure	**9,570.24**	**8,726.36**	**36,471.89**
3	**Profit from Operations before Interest, Foreign Exchange (gain) / loss (1-2)**	**825.79**	**234.08**	**3,309.55**
4	Interest (Net)	773.56	714.48	2,983.71
5	**Profit from Operations before Foreign Exchange (gain) / loss (3-4)**	**52.23**	**(480.40)**	**325.84**
6	Foreign Exchange (gain) / loss (Net)	(33.68)	(3.87)	(145.78)
7	**Profit / (Loss) before Tax (5-6)**	**85.91**	**(476.53)**	**471.62**
8	Tax Expense			
	(a) Current tax	17.19	-	94.00
	(b) Deferred Tax	-	-	-
	(c) MAT Credit entitlement	(17.19)	-	(94.00)
	(d) Excess provision of income tax no longer required	-	-	(37.39)
	(e) Wealth Tax	-	-	2.11
9	**Net Profit / (Loss) for the period (7-8)**	**85.91**	**(476.53)**	**506.90**
10	Paid-up Equity Share Capital (Face Value ₹10 per share)	546.71	546.71	546.71
11	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting			6,646.17
12	Earnings per Share (EPS)			
	(a) Basic	1.59	(8.83)	9.39
	(b) Diluted	1.59	(8.82)	9.38
13	Public Shareholding			
	(a) Number of Shares	3,444,717	3,345,833	3,444,717
	(b) Percentage of Shareholding	63.83%	62.00%	63.83%
14	Promoters and Promoter Group Shareholding			
	(a) Pledged / Encumbered			
	-Number of Shares	425,000	167,500	200,000
	-Percentage of Shares (as a % of the total shareholding of promoter and	21.78%	8.17%	10.25%
	-Percentage of Shares (as a % of the total share capital of the Company)	7.88%	3.10%	3.71%
	(b) Non-encumbered			
	-Number of Shares	1,526,738	1,883,122	1,751,738
	-Percentage of Shares (as a % of the total shareholding of promoter and	78.22%	91.83%	89.75%
	-Percentage of Shares (as a % of the total share capital of the Company)	28.29%	34.90%	32.46%

NEULAND LABORATORIES LIMITED

Flat No.204, II Floor, Meridian Plaza, 6-3-853/1, Ameerpet, Hyderabad-500 016. A.P., INDIA
Phone : +91-40-30211600, 23412934, 66518682, Fax : +91-40-23412957
E-mail : neuland@neulandlabs.com URL : www.neulandlabs.com

SEGMENT REVENUE, RESULTS AND CAPITAL EMPLOYED
UNDER CLAUSE 41 OF THE LISTING AGREEMENT

Amount in ₹ Lacs

Particulars	Quarter Ended 30.06.2011 (Unaudited)	Quarter Ended 30.06.2010 (Unaudited)	Year Ended 31.03.2011 (Audited)
SEGMENT REVENUE (NET SALES)			
(a) India	1,934.31	1,725.35	7,560.54
(b) Other than India	8,296.90	7,178.37	31,796.69
Total	**10,231.21**	**8,903.72**	**39,357.23**

NOTES:

1 The above unaudited financial results which have been subjected to a Limited Review by Statutory Auditors, were reviewed by the Audit Committee at their meeting held on August 4, 2011, and approved and taken on record at the Board of Directors meeting held on August 5, 2011.

2 One investor complaint was received and disposed off during the quarter. There were no investor complaints pending at the beginning and at the end of the quarter.

3 EPS for the quarters is not annualised.

4 The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment.

5 Previous quarter / year figures have been regrouped wherever necessary.

6 The Board of Directors of the Company at their meeting held on July 7, 2011 accorded consent to a rights issue of equity shares not exceeding ₹12 crores. The Board had also constituted a Rights issue committee to finalise the rights ratio, issue price, record date and other procedural modalities relating to the proposed rights issue.

By Order of the Board
For Neuland Laboratories Limited

Dr. D.R.Rao
Chairman & Managing Director

Place: Hyderabad
Date: August 5, 2011